Bruton's tyrosine kinase inhibition for the treatment of allergic disorders
IgE signaling through its high-affinity receptor FcεRI is central to the pathogenesis of numerous allergic disorders. Oral inhibitors of Bruton's tyrosine kinase (BTKis), which are currently FDA-approved for the treatment of B cell malignancies, broadly inhibit the FcεRI pathway in human mast c...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Revisão |
| Jazyk: | angličtina |
| Vydáno: |
2024
|
| On-line přístup: | https://doi.org/10.1016/j.anai.2024.03.002 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|